NASDAQ · COGT
Healthcare · Biotechnology
$29.51
Up+$0.16 (+0.54%)
Updated Oct 16, 2026, 7:28 PM
SID Score
4.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance · COGT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 15, 2026
COGT closed at $29.51 after 21 trading sessions, down 11.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | $28.33 | $29.78 | $28.33 | $29.51 | 3.04M |
| Oct 14, 2026 | $27.93 | $29.05 | $27.735 | $28.15 | 2.3M |
| Oct 13, 2026 | $29.46 | $29.46 | $27.85 | $28.09 | 3M |
| Oct 12, 2026 | $30.81 | $31.07 | $29.63 | $29.78 | 1.86M |
| Oct 9, 2026 | $29.98 | $31.03 | $29.90 | $31.00 | 2.52M |
| Oct 8, 2026 | $29.71 | $30.66 | $28.69 | $30.08 | 3.64M |
| Oct 7, 2026 | $30.05 | $30.43 | $29.88 | $30.14 | 1.26M |
| Oct 6, 2026 | $31.17 | $31.17 | $29.70 | $30.38 | 2.38M |
| Oct 5, 2026 | $31.26 | $31.37 | $29.93 | $30.87 | 1.79M |
| Oct 2, 2026 | $32.12 | $32.29 | $30.855 | $31.02 | 1.17M |
| Oct 1, 2026 | $32.02 | $32.57 | $31.52 | $31.59 | 1.7M |
| Sep 30, 2026 | $31.735 | $32.76 | $31.485 | $32.02 | 1.96M |
| Sep 29, 2026 | $31.76 | $32.12 | $31.32 | $31.66 | 1.7M |
| Sep 28, 2026 | $32.00 | $32.20 | $31.23 | $31.86 | 2.21M |
| Sep 25, 2026 | $31.55 | $32.71 | $31.05 | $32.31 | 2.98M |
| Sep 24, 2026 | $31.21 | $31.95 | $30.3501 | $31.43 | 2.59M |
| Sep 23, 2026 | $32.62 | $32.85 | $30.88 | $31.41 | 2.33M |
| Sep 22, 2026 | $32.23 | $32.85 | $32.06 | $32.63 | 2.04M |
| Sep 21, 2026 | $31.97 | $32.515 | $31.41 | $32.00 | 3.42M |
| Sep 18, 2026 | $33.21 | $33.42 | $31.39 | $31.50 | 4.6M |
| Sep 17, 2026 | $33.07 | $33.64 | $32.875 | $33.19 | 1.19M |
The latest Smart Investors Daily articles mentioning COGT.
Company
Market Activity
Research & News
COGT research
Company profile and research snapshot.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | Wedbush | Outperform | — |
| Sep 15, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 17, 2026 | Piper Sandler | Overweight | — |
| Aug 12, 2026 | Guggenheim | Buy | — |
| May 29, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 2, 2026
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 16.44% on an annualized basis producing an average annual return of 28.63%. Currently, Cogent Biosciences has a market capitalization
Yahoo · Sep 25, 2026
Cogent Biosciences has delivered very strong share price gains over the past five years, so the obvious question for you now is whether that move is backed up by what sits on its balance sheet. After a powerful run and fresh regulatory progress, investors are increasingly asking how today’s valuation stacks up against the company’s book value. Over the past 5 years the stock is up about 2.7x. This puts real pressure on the question of whether the current price is still in line with what its...
Yahoo · Sep 24, 2026
Cogent Biosciences (COGT) just received U.S. Food and Drug Administration acceptance of its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, with no advisory committee planned and no review issues flagged. Despite the FDA momentum, Cogent Biosciences shares have eased recently, with the 30 day share price return down 13.3% and the 90 day share price return down 17.4%. However, the 1 year total shareholder return of 137.1% suggests earlier optimism around its broader...
Yahoo · Sep 24, 2026
Cogent Biosciences recently announced that the FDA has accepted its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, set a PDUFA action date of June 29, 2027, and indicated no current plans for an advisory committee or identified review issues. The filing builds on pivotal APEX trial data showing clinically meaningful responses and durable clinical activity in Advanced Systemic Mastocytosis, while parallel NDA reviews in NonAdvanced SM and GIST point to a broader...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COGT.
